2024年4月3日 · PARP inhibitors are a type of targeted therapy commonly used to treat breast cancer and ovarian cancer, among others. They target PARP, or poly (ADP-ribose) polymerase, which is a protein in cells that helps repair damaged DNA.

PARP inhibitors are a call of drugs that are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP), which plays a role in repairing DNA in damaged cells. Medical uses of these drugs include the treatment of heritable cancers. [1] .

2025年1月20日 · What are PARP inhibitors? A PARP inhibitor is a cancer treatment that blocks a protein your body makes called PARP. “PARP” is short for “poly (ADP-ribose) polymerase.”PARP has an important job. If the DNA in a cell gets damaged, PARP helps repair it. These repairs are essential because DNA contains the genetic material (genes) that tell your cells how to work …

2023年4月14日 · A PARP inhibitor stops cancer cells being repaired which causes the cells to die and reduces tumor growth. How they work DNA damage and mutation occurs naturally and can lead to cancer.

2021年3月15日 · PARP inhibitors block the action of the PARP enzymes: PARP-1, PARP-2, and PARP-3. These all help repair damaged DNA in cells. PARP inhibitors can keep cancer cells from...

2020年9月9日 · PARP inhibitors (PARPi) were the first approved cancer drugs that specifically targeted the DNA damage response in BRCA1/2 mutated breast and ovarian cancers.

2022年1月12日 · PARP inhibitors are drugs that block the DNA-repairing mechanism of PARP. By preventing PARP from repairing the damaged DNA within cancer cells, PARP inhibitors can help kill them.

2024年9月24日 · PARP inhibitors are a type of targeted cancer drug. They are a treatment for several types of cancer including ovarian, breast and prostate cancer. They are also in trials as a treatment for other types of cancer.

PARP inhibitors act through synthetic lethality with mutations in DNA repair genes and were approved for the treatment of BRCA mutated ovarian and breast cancer. PARP inhibitors destabilize replication forks through PARP DNA entrapment and induce cell death through replication stress-induced mitotic catastrophe.

PARP inhibitors have emerged as a promising class of anticancer agents approved for the treatment of ovarian, breast, prostate, and pancreatic cancer. These inhibitors target PARP enzymes involved in DNA repair pathways and exhibit remarkable efficacy in cancers with genetic deficiencies in the homo …